Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin

Nature Communications

Volumn 4, Issue , 2013, Pages

  Pang, Baoxu ^a   Qiao, Xiaohang ^a   Janssen, Lennert ^a   Velds, Arno ^a   Groothuis, Tom ^a   Kerkhoven, Ron ^a   Nieuwland, Marja ^a   Ovaa, Huib ^a   Rottenberg, Sven ^a   Van Tellingen, Olaf ^a   Janssen, Jeroen ^b   Huijgens, Peter ^b   Zwart, Wilbert ^b   Neefjes, Jacques ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACLARUBICIN; DAUNORUBICIN; DNA TOPOISOMERASE; DOXORUBICIN; ETOPOSIDE; GRANZYME A; HISTONE; IDARUBICIN; INTERFERON; PROTEIN 14 3 3; PROTEIN P53; TRANSCRIPTION FACTOR NRF2; TRANSCRIPTOME;

CANCER; CHEMOTHERAPY; DRUG; ENZYME ACTIVITY; INHIBITOR; MITOCHONDRIAL DNA;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CHROMATIN; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG DISTRIBUTION; DRUG HALF LIFE; EPIGENETICS; GENETIC TRANSCRIPTION; HEART; HUMAN; HUMAN CELL; LIVER CELL; MOUSE; NATURAL KILLER CELL; NEOPLASM; NONHUMAN; NUCLEOSOME; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE;

ACLARUBICIN; ANIMALS; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLAST CRISIS; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATIN; DNA; DNA DAMAGE; DOXORUBICIN; ETOPOSIDE; HEART; HISTONES; HUMANS; INTERCALATING AGENTS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, NUDE; NUCLEIC ACID CONFORMATION; NUCLEOSOMES; ORGAN SPECIFICITY; TRANSCRIPTOME;

EID: 84878732407     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms2921     Document Type: Article

References (57)

1. Garnett, M. J. et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570-575 (2012)
2. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005). (Pubitemid 40559006)
3. Arcamone, F. et al. Adriamycin, 14-hydroxydaimomycin, a new antitumor antibiotic from S. Peucetius var. caesius. Biotechnol Bioeng. 11, 1101-1110 (1969)
4. Hande, K. R. Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim. Biophys. Acta. 1400, 173-184 (1998) (Pubitemid 28475102)
5. Minotti, G., Menna, P., Salvatorelli, E., Cairo, G. & Gianni, L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56, 185-229 (2004) (Pubitemid 38720829)
6. Arcamone, F.-M. Fifty years of chemical research at farmitalia. Chemistry 15, 7774-7791 (2009)
7. Nitiss, J. L. Targeting DNA topoisomerase II in cancer chemotherapy. Nat. Rev. Cancer 9, 338-350 (2009)
8. Misteli, T. & Soutoglou, E. The emerging role of nuclear architecture in DNA repair and genome maintenance. Nat. Rev. Mol. Cell. Biol. 10, 243-254 (2009)
9. Gianni, L. et al. Anthracycline cardiotoxicity: from bench to bedside. J. Clin. Oncol. 26, 3777-3784 (2008)
10. Tewey, K., Rowe, T., Yang, L., Halligan, B. & Liu, L. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226, 466-468 (1984) (Pubitemid 14012819)
11. Chen, G. L. et al. Nonintercalative antitumor drugs interfere with the breakagereunion reaction of mammalian DNA topoisomerase II. J. Biol. Chem. 259, 13560-13566 (1984) (Pubitemid 15221834)
12. Dantuma, N. P., Groothuis, T. A. M., Salomons, F. A. & Neefjes, J. A dynamic ubiquitin equilibrium couples proteasomal activity to chromatin remodeling. J. Cell. Biol. 173, 19-26 (2006)
13. Greene, R. F., Collins, J. M., Jenkins, J. F., Speyer, J. L. & Myers, C. E. Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. Cancer Res. 43, 3417-3421 (1983) (Pubitemid 13061607)
14. Hande, K. R. et al. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. Cancer Res. 44, 379-382 (1984) (Pubitemid 14177767)
15. Schroeder, P. et al. Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent. Cancer Chemother. Pharmacol. 53, 91-93 (2004) (Pubitemid 38161195)
16. Frederick, C. A. et al. Structural comparison of anticancer drug-DNA complexes: adriamycin and daunomycin. Biochemistry 29, 2538-2549 (1990) (Pubitemid 20100850)
17. Luger, K., Mader, A. W., Richmond, R. K., Sargent, D. F. & Richmond, T. J. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389, 251-260 (1997) (Pubitemid 27406632)
18. Celeste, A. et al. Genomic instability in mice lacking histone H2AX. Science 296, 922-927 (2002) (Pubitemid 34464900)
19. Stucki, M. et al. MDC1 directly binds phosphorylated histone H2AX to regulate cellular responses to DNA double-strand breaks. Cell 123, 1213-1226 (2005) (Pubitemid 41821780)
20. Dong, Z., Zhong, Q. & Chen, P.-L. The Nijmegen breakage syndrome protein is essential for Mre11 phosphorylation upon DNA damage. J. Biol. Chem. 274, 19513-19516 (1999)
21. Neijenhuis, S. et al. Mechanism of cell killing after ionizing radiation by a dominant negative DNA polymerase beta. DNA Repair (Amst) 8, 336-346 (2009)
22. Wlodek, D., Banath, J. & Olive, P. L. Comparison between pulsed-field and constant-field gel electrophoresis for measurement of DNA double-strand breaks in irradiated Chinese hamster ovary cells. Int. J. Radiat. Biol. 60, 779-790 (1991)
23. Ross, W. E. & Smith, M. C. Repair of deoxyribonucleic acid lesions caused by adriamycin and ellipticine. Biochem. Pharmacol. 31, 1931-1935 (1982) (Pubitemid 12123103)
24. Filion, G. J. et al. Systematic protein location mapping reveals five principal chromatin types in drosophila cells. Cell 143, 212-224 (2010)
25. Ernst, J. et al. Mapping and analysis of chromatin state dynamics in nine human cell types. Nature 473, 43-49 (2011)
26. Gaulton, K. J. et al. A map of open chromatin in human pancreatic islets. Nat. Genet. 42, 255-259 (2010)
27. Hurtado, A., Holmes, K. A., Ross-Innes, C. S., Schmidt, D. & Carroll, J. S. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat. Genet. 43, 27-33 (2011)
28. Shan, K., Lincoff, A. M. & Young, J. B. Anthracycline-induced cardiotoxicity. Ann. Intern. Med. 125, 47-58 (1996)
29. Creemers, E. E., Wilde, A. A. & Pinto, Y. M. Heart failure: advances through genomics. Nat. Rev. Genet. 12, 357-362 (2011)
30. Zhang, S. et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat. Med. 18, 1639-1642 (2012)
31. Ewen, M. E. Where the cell cycle and histones meet. Genes Dev. 14, 2265-2270 (2000)
32. Barry, S. P. & Townsend, P. A. in International Review of Cell and Molecular Biology Vol. 284Jeon Kwang, W. (ed. 113-179 (Academic Press, 2010)
33. Feenstra, J., Grobbee, D. E., Remme, W. J. & Stricker, B. H. C. Drug-induced heart failure. J. Am. Coll. Cardiol. 33, 1152-1162 (1999)
34. Bennett, J. M. et al. Long-term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group experience. Cancer 80, 2205-2209 (1997) (Pubitemid 27509592)
35. Rogakou, E. P., Nieves-Neira, W., Boon, C., Pommier, Y. & Bonner, W. M. Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139. J. Biol. Chem. 275, 9390-9395 (2000) (Pubitemid 30185164)
36. Gieseler, F. et al. Topoisomerase II activities in AML blasts and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines. Leukemia 10(Suppl 3): S46-S49 (1996) (Pubitemid 26288116)
37. Kaufmann, S. et al. Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. Blood 83, 517-530 (1994) (Pubitemid 24030580)
38. Meeks-Wagner, D. & Hartwell, L. H. Normal stoichiometry of histone dimer sets is necessary for high fidelity of mitotic chromosome transmission. Cell 44, 43-52 (1986) (Pubitemid 16036712)
39. Morillo-Huesca, M. et al. FACT prevents the accumulation of free histones evicted from transcribed chromatin and a subsequent cell cycle delay in G1. PLoS Genet. 6, e1000964 (2010)
40. Hansen, O. P. et al. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark. Leukemia 5, 510-516 (1991)
41. Weiss, R. B. The anthracyclines: will we ever find a better doxorubicin? Semin. Oncol. 19, 670-686 (1992) (Pubitemid 23004844)
42. Wu, C.-C. et al. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide. Science 333, 459-462 (2011)
43. Willmore, E., Frank, A. J., Padget, K., Tilby, M. J. & Austin, C. A. Etoposide targets topoisomerase IIa and IIb in leukemic cells: isoform-specific cleavable complexes visualized and quantified in Situ by a novel immunofluorescence technique. Mol. Pharmacol. 54, 78-85 (1998) (Pubitemid 28337589)
44. Pai, V. B. & Nahata, M. C. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Safety 22, 263-302 (2000) (Pubitemid 30213944)
45. Fang, T. C. et al. Histone H3 lysine 9 di-methylation as an epigenetic signature of the interferon response. J. Exp. Med. 209, 661-669 (2012)
46. Oberdoerffer, P. An age of fewer histones. Nat. Cell. Biol. 12, 1029-1031 (2010)
47. Lee, Michael J. et al. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 149, 780-794 (2012)
48. Baylin, S. B. & Jones, P. A. A decade of exploring the cancer epigenome - biological and translational implications. Nat. Rev. Cancer 11, 726-734 (2011)
49. Patterson, G. H. & Lippincott-Schwartz, J. A photoactivatable GFP for selective photolabeling of proteins and cells. Science 297, 1873-1877 (2002) (Pubitemid 35024347)
50. Christensen, M. O. et al. Dynamics of human DNA topoisomerases IIa and IIb in living cells. J. Cell. Biol. 157, 31-44 (2002) (Pubitemid 34847828)
51. Reits, E. A. J. & Neefjes, J. J. From fixed to FRAP: measuring protein mobility and activity in living cells. Nat. Cell. Biol. 3, 145-147 (2001)
52. Asperen, J. v., Tellingen, O. v., Tijssen, F., Schinkel, A. H. & Beijnen, J. H. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein. Br. J. Cancer. 79, 108-113 (1998) (Pubitemid 28566934)
53. Smyth, G. K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 1, 3 (2004)
54. Schmidt, D. et al. ChIP-seq: Using high-throughput sequencing to discover protein-DNA interactions. Methods 48, 240-248 (2009)
55. Boyle, A. P., Guinney, J., Crawford, G. E. & Furey, T. S. F-Seq: a feature density estimator for high-throughput sequence tags. Bioinformatics 24, 2537-2538 (2008)
56. Shin, H., Liu, T., Manrai, A. K. & Liu, X. S. CEAS: cis-regulatory element annotation system. Bioinformatics 25, 2605-2606 (2009)
57. Ye, T. et al. seqMINER: an integrated ChIP-seq data interpretation platform. Nucleic Acids Res. 39, e35 (2011).